MLTX MoonLake Immunotherapeutics
Pharmaceutical Preparations · Nasdaq · SEC CIK 1821586 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-29.9%
TTM EPS YoY-9.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-81.6%
ROA-57.3%
ROIC (approx.)-384.1%
Asset turnover—
Leverage & solvency
Liabilities / assets29.4%
Debt / equity0.26x
Current ratio9.13x
Interest coverage-28.98x
Cash quality & payout
Operating cash flow / net income0.89x
Accruals ratio-6.2%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $202.86M | $112.77M | $31.80M | $42.05M | — |
| SG&A expense | $41.97M | $30.32M | $22.32M | $23.01M | $4.57M |
| Operating income | -$244.83M | -$143.09M | -$54.12M | -$65.06M | -$4.57M |
| Interest expense | $7.25M | $0 | $0 | — | — |
| Pretax income | -$229.71M | -$120.96M | -$43.98M | -$64.47M | — |
| Income tax | $611,000 | $282,000 | $94,000 | $36,366 | — |
| Net income | -$227.32M | -$118.94M | -$36.01M | -$49.97M | -$4.54M |
| EBITDA | -$242.22M | -$141.71M | -$53.75M | -$64.90M | — |
| EPS (basic) | -3.53 | -1.89 | -0.73 | -1.70 | -0.31 |
| EPS (diluted) | -3.53 | -1.89 | -0.73 | -1.70 | -0.31 |
| Weighted avg. shares (diluted) | 64.46M | 62.87M | 49.12M | 29.36M | 360.00M |
| Balance sheet | |||||
| Cash & equivalents | $334.52M | $180.43M | $451.17M | $39.51M | $8.04M |
| Short-term investments | $59.45M | $267.60M | $59.84M | $32.61M | $0 |
| Current assets | $421.69M | $474.29M | $514.17M | $76.51M | $9.64M |
| PP&E, net | $577,000 | $722,000 | $320,865 | $49,389 | $45,739 |
| Total assets | $424.43M | $477.93M | $526.54M | $76.84M | $9.68M |
| Current liabilities | $45.48M | $22.46M | $9.97M | $7.67M | $21.09M |
| Short-term debt | — | — | — | $0 | $15.00M |
| Long-term debt | $74.10M | $0 | — | — | — |
| Total debt | $74.10M | $0 | — | — | — |
| Total liabilities | $119.95M | $24.54M | $13.05M | $8.08M | $21.33M |
| Shareholders' equity | $304.48M | $446.82M | $495.68M | $48.90M | -$11.65M |
| Net debt | -$260.42M | -$180.43M | — | — | — |
| Cash flow statement | |||||
| Operating cash flow | -$196.01M | -$116.59M | -$42.78M | -$55.89M | -$611,071 |
| Capital expenditure | $35,000 | $520,000 | $284,000 | $16,009 | — |
| Free cash flow | -$196.04M | -$117.11M | -$43.06M | -$55.91M | — |
| Investing cash flow | $202.99M | -$205.60M | -$25.18M | -$32.34M | — |
| Financing cash flow | $146.00M | $51.31M | $479.70M | $119.69M | -$58,063 |
| Depreciation & amortization | $2.62M | $1.39M | $370,000 | $164,783 | — |
| Stock-based compensation | $12.90M | $7.28M | $7.11M | $9.65M | — |
| Share buybacks | — | $50 | $0 | $0 | — |
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.